X.ZhangC
Limited preclinical and clinical data suggest that GLP-1 receptor agonists might modestly influence cortisol metabolism or HPA axis function in certain contexts, but findings have been inconsistent and not practice-changing
- Clarification If there are any unclear points, provide further explanations to remove confusion
The team consists of: Jennifer Smallridge (Exercise Physiologist) Sarah Lynch (Physiotherapist, Yoga Teacher) Jade Brodie (Physiotherapist, Hand Therapist) Together they bring expertise in chronic illness care coordination, safe exercise & movement support, pacing and fatigue management, chronic pain education, coaching and goal setting
Bi l y l mt thnh phn t nhin trn da, n c th c dung np thng qua thc phm, vin ung hoc m phm
The problem was the side effects associated, particularly with GLP-1, are what we call peak to trough: so the difference between the highest amount of drug and the lowest and then going back up again to the highest caused by this twice-a-day dosingwhich you can imagine someone bouncing around maybe two to three times, the drug at peak, then trough, causes a lot of GI distress
